Business Wire02.01.17
Lantheus Holdings Inc., parent company of Lantheus Medical Imaging Inc. (LMI), has appointed Julie McHugh as a member of its Board of Directors, effective Jan. 25. The company's board now consists of nine members.
McHugh, who will serve as a member of the board's Compensation Committee, has more than 30 years of experience in the pharmaceutical, biotech and medical devices industries. She recently served as chief operating officer of Endo Health Solutions Inc., where she was responsible for the specialty pharmaceutical and generic drug businesses. Prior to that, McHugh was CEO of Nora Therapeutics Inc., a venture capital-backed biotech startup company focused on developing therapies for the treatment of infertility disorders. Previously, she served as company group chairman for Johnson & Johnson's worldwide virology business unit, and prior to that, she was president of Centocor Inc., a J&J subsidiary. In this role, McHugh oversaw the development and launches of several products, including Remicade (infliximab), Prezista (darunavir) and Intelence (etravirine). Prior to joining Centocor, McHugh led the marketing communications for gastrointestinal drug Prilosec (omeprazole) at Astra-Merck Inc.
McHugh currently serves on the Board of Directors of Aerie Pharmaceuticals Inc., Ironwood Pharmaceuticals Inc., New Xellia Group A/S and Trevena Pharmaceuticals Inc. She previously served on the boards of the Biotechnology Industry Organization, the New England Healthcare Institute, the Pennsylvania Biotechnology Association, EPIRUS Pharmaceuticals Inc., and ViroPharma Inc.
McHugh received a master's degree in business administration from St. Joseph's University and a bachelor of science degree from Pennsylvania State University.
“We welcome Julie to the board, and I am confident she will be immensely valuable to our company and stakeholders,” said Mary Anne Heino, president and CEO. “In addition to her business expertise, Julie has a strong background in health policy, innovation and advocacy. We look forward to the industry perspective and strategic acumen Julie brings to the table.”
Lantheus Holdings Inc. is the parent company of Lantheus Medical Imaging Inc., a developer, manufacturer, and commercializer of diagnostic imaging agents and products. LMI provides a broad portfolio of products, which are primarily used for the diagnosis of cardiovascular diseases. LMI’s key products include the echocardiography contrast agent DEFINITY Vial for (Perflutren Lipid Microsphere) Injectable Suspension; TechneLite (Technetium Tc99m Generator), a technetium-based generator that provides the essential medical isotope used in nuclear medicine procedures; and Xenon (Xenon Xe 133 Gas), an inhaled radiopharmaceutical imaging agent used to evaluate pulmonary function and for imaging the lungs. Lantheus is headquartered in North Billerica, Mass., with offices in Puerto Rico and Canada.
McHugh, who will serve as a member of the board's Compensation Committee, has more than 30 years of experience in the pharmaceutical, biotech and medical devices industries. She recently served as chief operating officer of Endo Health Solutions Inc., where she was responsible for the specialty pharmaceutical and generic drug businesses. Prior to that, McHugh was CEO of Nora Therapeutics Inc., a venture capital-backed biotech startup company focused on developing therapies for the treatment of infertility disorders. Previously, she served as company group chairman for Johnson & Johnson's worldwide virology business unit, and prior to that, she was president of Centocor Inc., a J&J subsidiary. In this role, McHugh oversaw the development and launches of several products, including Remicade (infliximab), Prezista (darunavir) and Intelence (etravirine). Prior to joining Centocor, McHugh led the marketing communications for gastrointestinal drug Prilosec (omeprazole) at Astra-Merck Inc.
McHugh currently serves on the Board of Directors of Aerie Pharmaceuticals Inc., Ironwood Pharmaceuticals Inc., New Xellia Group A/S and Trevena Pharmaceuticals Inc. She previously served on the boards of the Biotechnology Industry Organization, the New England Healthcare Institute, the Pennsylvania Biotechnology Association, EPIRUS Pharmaceuticals Inc., and ViroPharma Inc.
McHugh received a master's degree in business administration from St. Joseph's University and a bachelor of science degree from Pennsylvania State University.
“We welcome Julie to the board, and I am confident she will be immensely valuable to our company and stakeholders,” said Mary Anne Heino, president and CEO. “In addition to her business expertise, Julie has a strong background in health policy, innovation and advocacy. We look forward to the industry perspective and strategic acumen Julie brings to the table.”
Lantheus Holdings Inc. is the parent company of Lantheus Medical Imaging Inc., a developer, manufacturer, and commercializer of diagnostic imaging agents and products. LMI provides a broad portfolio of products, which are primarily used for the diagnosis of cardiovascular diseases. LMI’s key products include the echocardiography contrast agent DEFINITY Vial for (Perflutren Lipid Microsphere) Injectable Suspension; TechneLite (Technetium Tc99m Generator), a technetium-based generator that provides the essential medical isotope used in nuclear medicine procedures; and Xenon (Xenon Xe 133 Gas), an inhaled radiopharmaceutical imaging agent used to evaluate pulmonary function and for imaging the lungs. Lantheus is headquartered in North Billerica, Mass., with offices in Puerto Rico and Canada.